Physician profile
Matthew S Rich
NPI 1639692965
$5,502.62
in general payments reported to CMS, 2019-2025
21 companies · $887 in 2025
The $887 reported for 2025 was more than what 82% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,873 · 2022: $1,319 · 2023: $803 · 2024: $621 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.93 | 2021-2025 | |
| Alkermes, INC. | $880.92 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $667.33 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $558.18 | 2021-2025 | Caplyta |
| Lundbeck LLC | $430.16 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $271.27 | 2022-2025 | Fanapt |
| Indivior INC. | $226.56 | 2021-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $207.53 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $190.37 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $130.67 | 2021-2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $130.17 | 2023-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $94.03 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $55.21 | 2023-2025 | Auvelity, Sunosi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.40 | 2022 | |
| Jazz Pharmaceuticals INC. | $42.02 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $40.58 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $27.04 | 2022 | |
| Biogen, INC. | $15.71 | 2024 | Zurzuvae |
| Noven Therapeutics, LLC | $13.52 | 2023 | Secuado |
| Amgen INC. | $13.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.